{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:49:25Z","timestamp":1789717765587,"version":"4.0.1"},"reference-count":818,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.eimc.2012.03.006","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T18:31:50Z","timestamp":1369938710000},"page":"e1-e89","source":"Crossref","is-referenced-by-count":12,"title":["Documento de consenso de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero de 2012)"],"prefix":"10.1016","volume":"30","member":"78","reference":[{"key":"10.1016\/j.eimc.2012.03.006_bib0005","series-title":"Tratamiento antirretroviral del adulto","year":"1997"},{"key":"10.1016\/j.eimc.2012.03.006_bib0010","first-page":"209.e1","article-title":"Documento de consenso de GESIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero 2011)","volume":"29","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib0020","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1-167 [consultado 15 Dic 2011]. Disponible en: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"10.1016\/j.eimc.2012.03.006_bib0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","article-title":"Guide to development of practice guidelines","volume":"32","author":"Kish","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, HIV Outpatient Study Investigators","volume":"338","author":"Palella Jr.","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0035","unstructured":"Knobel H, Polo R, Escobar I, coordinadores. Recomendaciones Gesida\/SEFH\/PNS para mejorar la adherencia al tratamiento antirretroviral (actualizaci\u00f3n junio de 2008) [consultado 15 Dic 2011]. Disponible en: http:\/\/www.gesida.seimc.org\/pcientifica\/fuentes\/DcyRc\/Gesida_dcyrc2008_adherenciaTAR.pdf"},{"key":"10.1016\/j.eimc.2012.03.006_bib0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","article-title":"Survival of persons with and without HIV infection in Denmark, 1995-2005","volume":"146","author":"Lohse","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0045","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","article-title":"Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies","volume":"373","author":"Sterne","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0050","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/QAI.0b013e31815ee282","article-title":"Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)","volume":"47","author":"Jaen","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0055","first-page":"229","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"Montessori","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.eimc.2012.03.006_bib0060","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/QCO.0b013e32833ff1d0","article-title":"Can HIV infection be eradicated through use of potent antiviral agents?","volume":"23","author":"Josefsson","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0065","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00126334-200406010-00007","article-title":"Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count","volume":"36","author":"Garcia","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0070","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0140-6736(05)60532-6","article-title":"Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study","volume":"352","author":"Plana","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0075","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archinte.165.10.1133","article-title":"Physician specialization and the quality of care for human immunodeficiency virus infection","volume":"165","author":"Landon","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0080","year":"2009","journal-title":"Compendium of evidence-based HIV prevention interventions"},{"issue":"Suppl 5","key":"10.1016\/j.eimc.2012.03.006_bib0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0213-005X(10)70048-3","article-title":"Indicadores de calidad asistencial de GESIDA para la atenci\u00f3n de personas infectadas por el VIH\/sida","volume":"28","author":"Von Wichmann","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/infdis\/173.2.321","article-title":"Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir","volume":"173","author":"Kelleher","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0095","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(97)10291-4","article-title":"Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease","volume":"351","author":"Li","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00002030-199818000-00001","article-title":"Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy","volume":"12","author":"Kostense","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0105","first-page":"375","article-title":"Restauraci\u00f3n inmunol\u00f3gica en pacientes con Sida. \u00bfR\u00e9quiem por las profilaxis?","volume":"113","author":"Pe\u00f1a","year":"1999","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimc.2012.03.006_bib0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200101183440301","article-title":"A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04\/98","volume":"344","author":"Lopez Bernaldo de Quiros","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002030-199904160-00001","article-title":"HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy","volume":"13","author":"Deeks","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0120","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/315334","article-title":"Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection","volume":"181","author":"Deeks","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(98)24010-4","article-title":"CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study","volume":"351","author":"Kaufmann","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0130","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1086\/313660","article-title":"Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy","volume":"30","author":"Garcia","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0135","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1086\/342695","article-title":"Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression","volume":"35","author":"Dronda","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1086\/510682","article-title":"Cirrhosis is associated with low CD4+ T cell counts: implications for HIV-infected patients with liver disease","volume":"44","author":"Gandhi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0145","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/509580","article-title":"The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients","volume":"44","author":"McGovern","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0150","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/520025","article-title":"Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?","volume":"45","author":"Bongiovanni","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0155","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/QAD.0b013e32826fb6fc","article-title":"Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count <200 cells\/microl when viral replication is suppressed","volume":"21","author":"D\u2019Egidio","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0160","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/00002030-199911120-00009","article-title":"The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program","volume":"13","author":"Brambilla","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-0320(19991015)38:5<231::AID-CYTO5>3.0.CO;2-Y","article-title":"Enumeration of CD4(+) T-cells in the peripheral blood of HIV-infected patients: an interlaboratory study of the FACSCount system","volume":"38","author":"Lopez","year":"1999","journal-title":"Cytometry"},{"key":"10.1016\/j.eimc.2012.03.006_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00002030-199805000-00001","article-title":"The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir","volume":"12","author":"Kempf","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0175","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/00002030-199813000-00008","article-title":"Suppression of plasma viral load below 20 copies\/ml is required to achieve a long-term response to therapy","volume":"12","author":"Raboud","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0180","doi-asserted-by":"crossref","first-page":"954","DOI":"10.7326\/0003-4819-135-11-200112040-00007","article-title":"Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320","volume":"135","author":"Demeter","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0185","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/320192","article-title":"Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy","volume":"183","author":"Huang","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00002030-200403260-00008","article-title":"Long-term safety and durable antiretroviral activity of lopinavir\/ritonavir in treatment-naive patients: 4 year follow-up study","volume":"18","author":"Hicks","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0195","first-page":"96","article-title":"Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution","volume":"13","author":"Siliciano","year":"2005","journal-title":"Top HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0200","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1086\/423388","article-title":"Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy","volume":"39","author":"Nettles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0205","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/00002030-200209270-00017","article-title":"Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy","volume":"16","author":"Greub","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0210","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QAI.0b013e3180654836","article-title":"Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy","volume":"45","author":"Jones","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.286.2.171","article-title":"Prevalence and predictive value of intermittent viremia with combination HIV therapy","volume":"286","author":"Havlir","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib0220","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/00002030-200303280-00021","article-title":"Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies\/ml followed for up to 4 years","volume":"17","author":"Lampe","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135965350200700404","article-title":"Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure","volume":"7","author":"Mira","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib0230","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jinf.2004.11.010","article-title":"Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy","volume":"51","author":"Macias","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.eimc.2012.03.006_bib0240","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkm516","article-title":"Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome","volume":"61","author":"Garcia-Gasco","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib0245","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nm0696-625","article-title":"HIV viral load markers in clinical practice","volume":"2","author":"Saag","year":"1996","journal-title":"Nat Med"},{"issue":"Suppl 5","key":"10.1016\/j.eimc.2012.03.006_bib0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00002030-200100005-00021","article-title":"Therapeutic drug monitoring as a tool in treating HIV infection","volume":"15","author":"Khoo","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0255","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/501458","article-title":"Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring","volume":"42","author":"Nettles","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0260","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7326\/0003-4819-124-12-199606150-00003","article-title":"The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients","volume":"124","author":"Schapiro","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0265","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00002030-199811000-00002","article-title":"The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy","volume":"12","author":"Hoetelmans","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00002030-200201040-00007","article-title":"Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen","volume":"16","author":"Casado","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0275","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1086\/515317","article-title":"A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy","volume":"177","author":"Harris","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0280","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/00002030-199908200-00007","article-title":"Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients","volume":"13","author":"Fatkenheuer","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0285","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200106150-00003","article-title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","volume":"15","author":"Veldkamp","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0290","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.48.3.918-923.2004","article-title":"Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects","volume":"48","author":"DiCenzo","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2003.22","article-title":"Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection","volume":"73","author":"Csajka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib0300","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002030-199903110-00005","article-title":"Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients","volume":"13","author":"Dieleman","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0305","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00002030-200201250-00020","article-title":"Liver toxicity caused by nevirapine","volume":"16","author":"Gonzalez de Requena","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0310","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1089\/0889222041524562","article-title":"Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection","volume":"20","author":"Gonzalez-Requena","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2012.03.006_bib0315","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/00126334-200308150-00007","article-title":"Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir\/ritonavir-containing regimens","volume":"33","author":"Gutierrez","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0320","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/108729103322395465","article-title":"Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir\/ritonavir","volume":"17","author":"Gonzalez de Requena","year":"2003","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0325","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1086\/380791","article-title":"Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz","volume":"38","author":"Gallego","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0330","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0335","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1073\/pnas.90.9.4171","article-title":"Rates of spontaneous mutation among RNA viruses","volume":"90","author":"Drake","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eimc.2012.03.006_bib0340","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/genetics\/148.4.1667","article-title":"Rates of spontaneous mutation","volume":"148","author":"Drake","year":"1998","journal-title":"Genetics"},{"key":"10.1016\/j.eimc.2012.03.006_bib0345","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/JVI.69.8.5087-5094.1995","article-title":"Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase","volume":"69","author":"Mansky","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0350","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.eimc.2012.03.006_bib0355","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.eimc.2012.03.006_bib0360","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.eimc.2012.03.006_bib0365","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.eimc.2012.03.006_bib0370","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)","volume":"171","author":"Schuurman","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0375","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nm0796-760","article-title":"Ordered accumulation of mutations in HIV protease confers resistance to ritonavir","volume":"2","author":"Molla","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0380","first-page":"125","article-title":"Update of drug resistance mutations in HIV-1: Fall 2006","volume":"14","author":"Johnson","year":"2006","journal-title":"Top HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel","volume":"37","author":"Hirsch","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0390","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00002030-199912240-00001","article-title":"Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy","volume":"13","author":"Devereux","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0395","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/JCM.40.1.31-35.2002","article-title":"Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1","volume":"40","author":"Qari","year":"2002","journal-title":"J Clin Microbiol"},{"issue":"Suppl 3","key":"10.1016\/j.eimc.2012.03.006_bib0400","first-page":"49","article-title":"Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (Virtual Phenopyte)","volume":"5","author":"Larder","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib0405","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/427212","article-title":"Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy","volume":"40","author":"Novak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0410","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0415","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bmj.38665.534595.55","article-title":"Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study","volume":"331","author":"Cane","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2012.03.006_bib0420","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/496982","article-title":"Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain","volume":"41","author":"De Mendoza","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1157\/13116750","article-title":"Prevalencia de mutaciones de resistencia primaria en los nuevos diagn\u00f3sticos de infecci\u00f3n por el VIH en la provincia de M\u00e1laga","volume":"26","author":"Palacios","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0430","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1157\/13108707","article-title":"Resistencias primarias a los f\u00e1rmacos antirretrovirales en los pacientes diagnosticados de infecci\u00f3n por el VIH en Gran Canaria entre los a\u00f1os 2002-2005","volume":"25","author":"S\u00e1nchez O\u00f1oro","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0435","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2011.05.010","article-title":"Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naive HIV-infected individuals (CoRIS)","volume":"91","author":"Garcia","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eimc.2012.03.006_bib0440","doi-asserted-by":"crossref","first-page":"10747","DOI":"10.1128\/JVI.01827-07","article-title":"Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations","volume":"82","author":"Mitsuya","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0445","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcv.2009.03.002","article-title":"Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure","volume":"45","author":"Balduin","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0450","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/QAI.0b013e3181ba11e8","article-title":"Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy","volume":"52","author":"Geretti","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0455","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"Simen","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0460","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/595703","article-title":"Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients","volume":"48","author":"Metzner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0465","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1086\/596486","article-title":"Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"48","author":"Coovadia","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0470","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/QAD.0b013e3283034953","article-title":"Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy","volume":"22","author":"Peuchant","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0475","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0480","first-page":"77","article-title":"European recommendations for the clinical use of HIV drug resistance testing: 2011 update","volume":"13","author":"Vandamme","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2012.03.006_bib0485","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib0490","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy, AIDS Clinical Trials Group Study 343 Team","volume":"339","author":"Havlir","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0495","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002030-200002180-00005","article-title":"Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors","volume":"14","author":"Huisman","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0500","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS","volume":"14","author":"Baxter","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/135965350000500102","article-title":"Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up","volume":"5","author":"Clevenbergh","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib0510","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00002030-200201250-00010","article-title":"Clinical utility of HIV-1 genotyping and expert advice: the Havana trial","volume":"16","author":"Tural","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0515","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00002030-200203080-00009","article-title":"A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy","volume":"16","author":"Cohen","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0520","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00002030-200202150-00008","article-title":"Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)","volume":"16","author":"Cingolani","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0525","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00002030-200103300-00010","article-title":"Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors","volume":"15","author":"Kemper","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0530","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00002030-200203290-00008","article-title":"Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial","volume":"16","author":"Meynard","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0535","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00126334-200303010-00005","article-title":"Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial","volume":"32","author":"Mazzotta","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0540","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350300800604","article-title":"Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study","volume":"8","author":"Perez-Elias","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/FY66-NVWJ-3332-HW3C","article-title":"Antiretroviral drug resistance testing in patients with HIV-1 infection: A meta-analysis study","volume":"3","author":"Torre","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib0550","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1K522","article-title":"Abacavir hypersensitivity reaction: an update","volume":"42","author":"Hughes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2012.03.006_bib0555","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0560","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0565","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/088922204322749567","article-title":"The CCR5 and CXCR4 coreceptors \u2014central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection","volume":"20","author":"Moore","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2012.03.006_bib0570","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.185.4.621","article-title":"Change in coreceptor use coreceptor use correlates with disease progression in HIV-1 \u2014infected individuals","volume":"185","author":"Connor","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0575","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/507312","article-title":"Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia","volume":"194","author":"Hunt","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0580","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/511035","article-title":"HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211","volume":"44","author":"Wilkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0585","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism","volume":"51","author":"Whitcomb","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib0590","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e3282ef81ea","article-title":"Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates","volume":"21","author":"Low","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0595","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/jmv.21425","article-title":"Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools","volume":"81","author":"Chueca","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0600","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jac\/dkp063","article-title":"Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists","volume":"63","author":"Poveda","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib0605","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkq137","article-title":"High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists","volume":"65","author":"Seclen","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib0610","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1097\/QAD.0b013e32833e6cfb","article-title":"Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies","volume":"24","author":"McGovern","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0615","series-title":"17th Conference on Retroviruses and Opportunistic Infections","article-title":"Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity trofile assay in predicting virologic response to maraviroc of treatment-naive patients in the MERIT trial","author":"McGovern","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib0620","first-page":"135","article-title":"Genotypic determination of HIV tropism \u2014clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists","volume":"12","author":"Poveda","year":"2010","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2012.03.006_bib0625","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","article-title":"European guidelines on the clinical management of HIV-1 tropism testing","volume":"11","author":"Vandekerckhove","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0630","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11908-002-0071-6","article-title":"Treatment of primary HIV","volume":"4","author":"Stekler","year":"2002","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.eimc.2012.03.006_bib0635","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1172\/JCI21540","article-title":"Acute HIV revisited: new opportunities for treatment and prevention","volume":"113","author":"Pilcher","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eimc.2012.03.006_bib0640","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1086\/420745","article-title":"Primary HIV Type 1 Infection","volume":"38","author":"Kassutto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0645","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.163.17.2097","article-title":"Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings","volume":"163","author":"Weintrob","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0650","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0213-005X(04)73164-X","article-title":"Avances en el diagn\u00f3stico y tratamiento de la infecci\u00f3n aguda por el VIH-1","volume":"22","author":"Miro","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0655","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra1011874","article-title":"Acute HIV-1 Infection","volume":"364","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0660","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eimc.2011.10.009","article-title":"Manejo cl\u00ednico de la infecci\u00f3n aguda y cr\u00f3nica por el virus de la inmunodeficiencia humana antes del inicio del tratamiento antirretroviral","volume":"29","author":"Miro","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0665","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1097\/00002030-200010200-00014","article-title":"Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group","volume":"14","author":"Lindback","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0670","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-134-1-200101020-00010","article-title":"Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network","volume":"134","author":"Daar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0675","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/503258","article-title":"Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women","volume":"42","author":"Lavreys","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0680","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1086\/500213","article-title":"CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients","volume":"42","author":"Goujard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0685","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1758-2652-14-40","article-title":"Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters","volume":"14","author":"Socias","year":"2011","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.eimc.2012.03.006_bib0690","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/595704","article-title":"Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection","volume":"48","author":"Dalmau","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0695","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/QAI.0b013e3181989a8b","article-title":"Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection","volume":"50","author":"Goetz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0700","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(05)74227-6","article-title":"Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report","volume":"365","author":"Markowitz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0705","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1172\/JCI45235","article-title":"Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque","volume":"121","author":"Rotger","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eimc.2012.03.006_bib0710","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(04)15596-7","article-title":"Dual HIV-1 infection associated with rapid disease progression","volume":"363","author":"Gottlieb","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0715","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.1143767","article-title":"A whole-genome association study of major determinants for host control of HIV-1","volume":"317","author":"Fellay","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.eimc.2012.03.006_bib0720","doi-asserted-by":"crossref","first-page":"e1000791","DOI":"10.1371\/journal.pgen.1000791","article-title":"Common genetic variation and the control of HIV-1 in humans","volume":"5","author":"Fellay","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0725","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/QCO.0b013e3282f428bf","article-title":"Primary HIV infection: to treat or not to treat?","volume":"21","author":"Fidler","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0730","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/QAD.0b013e328338e4de","article-title":"HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men","volume":"24","author":"Rieder","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0735","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0740","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1468-1293.2009.00708.x","article-title":"Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men","volume":"10","author":"Fox","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0745","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.193.2.169","article-title":"Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection","volume":"193","author":"Altfeld","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0750","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1086\/320759","article-title":"Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection","volume":"32","author":"Cohen","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0755","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/00002030-200109070-00007","article-title":"Distribution of functional HIV-specific CD8 T lymphocytes between blood and secondary lymphoid organs after 8-18 months of antiretroviral therapy in acutely infected patients","volume":"15","author":"Oxenius","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0760","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/1521-4141(200112)31:12<3782::AID-IMMU3782>3.0.CO;2-#","article-title":"Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection","volume":"31","author":"Oxenius","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0765","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/35035103","article-title":"Immune control of HIV-1 after early treatment of acute infection","volume":"407","author":"Rosenberg","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.eimc.2012.03.006_bib0770","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nri2674","article-title":"The immune response during acute HIV-1 infection: clues for vaccine development","volume":"10","author":"McMichael","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0775","first-page":"e484","article-title":"Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection","volume":"3","author":"Mehandru","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib0780","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00002030-200403260-00001","article-title":"Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?","volume":"18","author":"Smith","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0785","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1086\/506625","article-title":"Treatment of acute HIV-1 infection: is it coming of age?","volume":"194","author":"Kinloch-de","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0790","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1468-1293.2008.00576.x","article-title":"Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome","volume":"9","author":"Voirin","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0795","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/500410","article-title":"Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection","volume":"42","author":"Kassutto","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0800","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0213-005X(06)73769-7","article-title":"Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003)","volume":"24","author":"Sued","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0805","doi-asserted-by":"crossref","first-page":"e18164","DOI":"10.1371\/journal.pone.0018164","article-title":"Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors","volume":"6","author":"Cellerai","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib0810","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/00002030-200210180-00010","article-title":"Virological and immunological effects of short course antiretroviral therapy in primary HIV infection","volume":"16","author":"Fidler","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0815","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.aids.0000200530.71737.75","article-title":"Comparative potency of three antiretroviral therapy regimes in primary HIV infection","volume":"20","author":"Fidler","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0820","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/QAI.0b013e3181963ae6","article-title":"Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection","volume":"50","author":"Apuzzo","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0825","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib0830","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"A randomized open-label trial of 5-drug vs 3-drug standard PI-based cART initiated during acute and early HIV-1 infection: 48-week results","author":"Markowitz","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib0835","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Immunological Effects of Treatment Intensification with MVC in Recently Infected HIV-1-naive Subjects Starting RAL+TDF\/FTC: The Maraviboost Study","author":"Masanella","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib0840","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/QAD.0b013e328326ca77","article-title":"Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France","volume":"23","author":"Chaix","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0845","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eimc.2011.03.001","article-title":"Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005","volume":"29","author":"Romero","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib0850","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00002030-200101260-00024","article-title":"Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection","volume":"15","author":"Goujard","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0855","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1097\/00002030-200010200-00025","article-title":"Lipodystrophy following antiretroviral therapy of primary HIV infection","volume":"14","author":"Miller","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0860","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2001.tb03914.x","article-title":"Metabolic and morphologic disorders in patients treated with highly active antiretroviral therapy since primary HIV infection","volume":"946","author":"Narciso","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.eimc.2012.03.006_bib0865","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1086\/503811","article-title":"Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection","volume":"194","author":"Streeck","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0870","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/342559","article-title":"Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination","volume":"186","author":"Markowitz","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0875","first-page":"2361","article-title":"Does transient HAART during primary HIV-1 infection lower the virological set-point?","volume":"18","author":"Desquilbet","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0880","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1086\/506616","article-title":"A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection","volume":"194","author":"Hecht","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0885","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Early treatment of primary HIV-1 infection lowers the viral set point","author":"Steingrover","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib0890","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"No Benefit from Early Treatment in Primary HIV-Infection?","author":"Koegl","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib0895","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"CD4 T-cell count increase during HAART initiated in primary infection in transient after-long term HAART interruption","author":"Seng","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib0900","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/135965350701200213","article-title":"Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study","volume":"12","author":"Lampe","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib0905","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Clinical outcomes of ART initiated during primary HIV infection","author":"Stekler","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib0910","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Can HAART Initiation at Early Acute HIV Infection Benefit the Immune-virology Outcome Despite Subsequent Treatment Cessation?.The ANRS Reservoirs Study Gro*up","author":"Prazuck","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib0915","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Early Short-course HAART Initiated at the Time of Primary HIV Infection Provides No Sustained Benefit in Terms of Time to CD4 Decline below 350\/mm3: Results of a Propensity Analysis within the ANRS PRIMO Cohort","author":"Desquilbet","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib0920","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1365-2249.2008.03653.x","article-title":"Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection","volume":"152","author":"Fox","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0925","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/QAD.0b013e328319ea4e","article-title":"The effect of antiretroviral treatment of different durations in primary HIV infection","volume":"22","author":"Pantazis","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0930","series-title":"6th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"The effect of short-course antiretroviral therapy in primary HIV infection: final results from an international randomised controlled trial (SPARTAC)","author":"Fidler","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib0935","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/infdis\/jir699","article-title":"The Setpoint Study (ACTG A5217): Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals","volume":"205","author":"Hogan","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0940","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1371\/journal.pmed.0010036","article-title":"Limited durability of viral control following treated acute HIV infection","volume":"1","author":"Kaufmann","year":"2004","journal-title":"PLoS Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib0945","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/00002030-200305020-00021","article-title":"Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection","volume":"17","author":"Tremblay","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0950","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000182628.66713.31","article-title":"Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial","volume":"40","author":"Hoen","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib0955","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/00002030-200107270-00014","article-title":"Early control of HIV replication in primary HIV-Infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study","volume":"15","author":"Emilie","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0960","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1086\/338123","article-title":"Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus specific responses in patients treated during recently acquired HIV infection","volume":"185","author":"Dybul","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib0965","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1189\/jlb.1007675","article-title":"Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection","volume":"83","author":"Adalid-Peralta","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.eimc.2012.03.006_bib0970","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00002030-200003310-00021","article-title":"Effects of hidroxiurea on T cell count changes during primary HIV infection","volume":"14","author":"Ravot","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib0975","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1172\/JCI0214522","article-title":"Treatment of primary HIV-1 infection with ciclosporin A coupled with HAART","volume":"109","author":"Rizzardi","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eimc.2012.03.006_bib0980","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"An open-label randomized trial to determine the virologic and immunologic effects of 4-weeks of cyclosporine A given in combination with ART During Acute And Early Infection","author":"Markowitz","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib0985","series-title":"16th Conference on Retroviruses and Opportunistic Infections","article-title":"Randomized clinical trial with immune-based therapy in patients with primary HIV-1 infection","author":"Miro","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib0990","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.eimc.2012.03.006_bib0995","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm806","article-title":"Therapeutic dendritic-cell vaccine for simian AIDS","volume":"9","author":"Lu","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1000","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/432002","article-title":"Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection","volume":"192","author":"Kinloch-de","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4161\/hv.1.6.2342","article-title":"Randomized, placebo-controlled, phase I\/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects","volume":"1","author":"Emery","year":"2005","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.eimc.2012.03.006_bib1010","doi-asserted-by":"crossref","first-page":"e10555","DOI":"10.1371\/journal.pone.0010555","article-title":"Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute\/early HIV-1 infection","volume":"5","author":"Rosenberg","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib1015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.eimc.2012.03.006_bib1020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00002030-199902250-00015","article-title":"The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection","volume":"13","author":"Paul","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1025","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","article-title":"Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group","volume":"352","author":"Mocroft","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archinte.166.5.521","article-title":"Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002","volume":"166","author":"Lampe","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e318134257a","article-title":"HIV-infected adults with a CD4 cell count greater than 500 cells\/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population","volume":"46","author":"Lewden","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/513823","article-title":"Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy","volume":"177","author":"Marschner","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1050","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1055","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/586713","article-title":"Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study","volume":"197","author":"Emery","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMoa0910370","article-title":"Early versus standard antiretroviral therapy for HIV-infected adults in Haiti","volume":"363","author":"Severe","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1065","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","article-title":"Effect of early versus deferred antiretroviral therapy for HIV on survival","volume":"360","author":"Kitahata","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1070","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/QAD.0b013e3282f7cb76","article-title":"CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection","volume":"22","author":"Baker","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1075","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1097\/QAD.0b013e3283112b77","article-title":"HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies","volume":"22","author":"Monforte","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1080","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/QAD.0b013e32832e9b78","article-title":"Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy","volume":"23","author":"Marin","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1085","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the risk of death after HIV seroconversion compared with mortality in the general population","volume":"300","author":"Bhaskaran","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib1095","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","article-title":"Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies","volume":"21","author":"May","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1100","series-title":"6th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Temporal trends in liver-related mortality in a prospective cohort of HIV-infected patients in Spain 1997-2008 \u2014 Oral Abstract","author":"Berenguer","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib1105","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.amjmed.2008.05.027","article-title":"The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy","volume":"121","author":"Bra\u00f1as","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-1293.2006.00397.x","article-title":"CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells\/\u03bcL","volume":"7","author":"Moore","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0b013e31804d685b","article-title":"CD4 cell counts of 800 cells\/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells\/mm3 or greater","volume":"45","author":"Gras","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(07)60948-9","article-title":"Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study","volume":"370","author":"Mocroft","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/QAI.0b013e31815acacc","article-title":"Initiation of antiretroviral therapy at CD4 cell counts \u2265350 cells\/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency","volume":"47","author":"Lichtenstein","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1130","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/01.aids.0000247578.08449.ff","article-title":"An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults","volume":"20","author":"Bartlett","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1135","series-title":"Gu\u00eda pr\u00e1ctica del sida cl\u00ednica, diagn\u00f3stico y tratamiento","author":"Gatell Artigas","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib1140","unstructured":"Coffey S, Peipert L. Antiretroviral drug profiles. HIV Knowledge Base [consultado 15 Dic 2011]. Disponible en: http:\/\/hivinsite.ucsf.edu\/InSite?page=ar-drugs"},{"key":"10.1016\/j.eimc.2012.03.006_bib1145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00002030-200501280-00017","article-title":"Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine","volume":"19","author":"Leon","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(04)16591-4","article-title":"Pancreatic toxic effects associated with the co-administration of didanosine and tenofovir in HIV-infected adults","volume":"364","author":"Martinez","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/135965350501000117","article-title":"Early virological failure with a combination of tenofovir, didanosine and efavirenz","volume":"10","author":"Podzamczer","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib1165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine\/lamivudine and efavirenz in treatment-naive patients: 144-week analysis","volume":"47","author":"Arribas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1170","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":"Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults","volume":"39","author":"DeJesus","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.qai.0000147521.34369.c9","article-title":"Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study","volume":"38","author":"Moyle","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1180","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1185","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1190","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1195","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jir505","article-title":"Abacavir\/lamivudine versus tenofovir DF\/emtricitabine as part of combination regimens for initial treatment of HIV: final results","volume":"204","author":"Sax","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1200","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study","volume":"55","author":"Post","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1468-1293.2009.00724.x","article-title":"Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients","volume":"10","author":"Hill","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1215","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1220","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collabration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1225","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1230","first-page":"11","article-title":"Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study","author":"Obel","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1235","first-page":"170","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4","author":"Lang","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1240","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"No association of myocardial infarction with ABC use: An FDA meta-analysis","author":"Ding","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib1245","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/QAI.0b013e31819ff0e6","article-title":"Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects","volume":"51","author":"Brothers","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1250","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","article-title":"Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data","volume":"25","author":"Cruciani","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1255","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/cid\/ciq244","article-title":"No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001\/ALLRT","volume":"52","author":"Ribaudo","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1260","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of secuential three-drug regimens as inicial therapy for HIV-1 infecti\u00f3n","volume":"349","author":"Robbins","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1265","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa030265","article-title":"Comparison of four-drug regimens and pairs of sequential three-drugs regimens as inicial therapy for HIV-1 infection","volume":"349","author":"Shafer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1270","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1086\/592114","article-title":"Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903","volume":"47","author":"Berenguer","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1275","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial","volume":"368","author":"Eron Jr.","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1280","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/aid.2008.0231","article-title":"Comparison of once-daily fosamprenavir boosted with either 100 or 200mg of ritonavir, in combination with abacavir\/lamivudine: 96-week results from COL100758","volume":"25","author":"Hicks","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2012.03.006_bib1285","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1310\/hct0903-152","article-title":"Once-daily abacavir\/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study","volume":"9","author":"Elion","year":"2008","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1290","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1295","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.296.7.769","article-title":"Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial","volume":"296","author":"Gulick","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib1300","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.285.9.1155","article-title":"Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial","volume":"285","author":"Staszewski","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib1305","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/aid.2007.0271","article-title":"Zidovudine\/lamivudine\/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study","volume":"24","author":"Ferrer","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2012.03.006_bib1310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350601100106","article-title":"An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy","volume":"11","author":"Moyle","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1315","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/01.qai.0000243092.40490.26","article-title":"Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir\/ritonavir, or stavudine","volume":"43","author":"Bartlett","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1320","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1086\/498069","article-title":"Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects","volume":"192","author":"Gallant","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1325","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1097\/00002030-200309260-00005","article-title":"Low efficacy and high frequency of adverse events in a randomized trial of the triple NRTI regimen abacavir, stavudine and didanosine","volume":"17","author":"Gerstoft","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1330","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":"Nevirapine versus atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial","volume":"16","author":"Soriano","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1335","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa0906626","article-title":"Antiretroviral therapies in women after single-dose nevirapine exposure","volume":"363","author":"Lockman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1340","series-title":"17th Conference on Retroviruses and Opportunistic Infections","article-title":"Efficacy of ART with NVP+TDF\/FTC vs LPV\/r+TDF\/FTC among antiretroviral na\u00efve womwn in Africa: OCTANE trial 2\/ACTG A5208","author":"McIntyre","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib1345","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/135965350200700202","article-title":"A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine\/lamivudine in HIV-infected naive patients (the Combine Study)","volume":"7","author":"Podzamczer","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1350","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1310\/DNVE-H4RG-6FPP-R9RQ","article-title":"Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads","volume":"2","author":"Raffi","year":"2001","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1355","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1360","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team","volume":"341","author":"Staszewski","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1365","first-page":"36","article-title":"Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule\/ritonavir in antiretroviral-naive, HIV-infected patients","volume":"8","author":"Montaner","year":"2006","journal-title":"MedGenMed"},{"key":"10.1016\/j.eimc.2012.03.006_bib1370","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1375","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1097\/QAD.0b013e32834c4c06","article-title":"Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results","volume":"25","author":"Gazzard","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1380","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"Van Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1385","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00126334-200404010-00003","article-title":"Clinical, virologic, and immunologic response to efavirenz or protease inhibitor based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study)","volume":"35","author":"Pulido","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1390","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/QAI.0b013e3181cae4a1","article-title":"Prospective, randomized, open label trial of Efavirenz vs Lopinavir\/Ritonavir in HIV+ treatment-naive subjects with CD4 \u2264200 cell\/mm3 in Mexico","volume":"53","author":"Sierra-Madero","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1395","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1400","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/QAI.0b013e31819c2937","article-title":"A once-daily lopinavir\/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks","volume":"50","author":"Gathe","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1405","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200401010-00003","article-title":"The NEAT Study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy na\u00efve HIV-1-infected patients","volume":"35","author":"Rodriguez-French","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1410","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.aids.0000131332.30548.92","article-title":"SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir\/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients","volume":"18","author":"Gathe","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1415","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Determination of body composition changes by total body DEXA after 48 weeks of treatment with once-daily fosamprenavir (FPV) boosted with two different doses of ritonavir(r) plus abacavir (ABC)\/lamivudine(3TC): COL100758","author":"Wohl","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib1420","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/AAC.00560-06","article-title":"Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers","volume":"51","author":"Ruane","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib1425","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1430","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-na\u00efve. HIV-1-infected patients: 96-week analysis","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1435","series-title":"10th International Congess on Drug Therapy in HIV Infection","article-title":"ARTEMIS: 192-week efficacy and safety of once-daily darunavir\/ritonavir vs lopinavir\/r in treatment-na\u00efve HIV-1-infected adults","author":"Orkin","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib1440","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e318198a815","article-title":"Gemini: a noninferiority study of saquinavir\/ritonavir versus lopinavir\/ritonavir as initial HIV-1 therapy in adults","volume":"50","author":"Walmsley","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1445","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e31815ace6a","article-title":"Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients","volume":"47","author":"Malan","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1450","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1455","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","article-title":"Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study","volume":"53","author":"Molina","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1460","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1465","doi-asserted-by":"crossref","DOI":"10.1310\/hct1103-125","article-title":"Efficacy and safety of maraviroc versus efavirenz, both with zidovudine\/lamivudine: 96-week results from the MERIT study","volume":"11","author":"Sierra-Madero","year":"2010","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1470","series-title":"48th Annual ICCAC\/IDSA 46th Annual Meeting","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-na\u00efve HIV-1-infected patients","author":"Lennox","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib1475","series-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Durable and consistent efficacy of raltegravir with tenofovir and emtricitabine across demographic and baseline prognostic factors in treatment-na\u00efve patients from STARTMRK at Wk 156","author":"Lazzarin","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib1480","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"QDMRK, a phase III study of the safety and efficacy of once daily vs twice daily RAL in combination therapy for treatment-na\u00efve HIV-infected patients","author":"Eron","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib1485","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAD.0b013e3282f3f16d","article-title":"Lopinavir\/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients","volume":"22","author":"Delfraissy","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1490","series-title":"18th International AIDS Conference","article-title":"The SPARTAN study: a pilot study to assess the safety and effi cacy of an investigational NRTI- and RTV-sparing regimen of atazanavir experimental dose of 300mg BID plus raltegravir 400mg BID in treatment-na\u00efve HIV-infected subjects","author":"Kozal","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib1495","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1310\/hct1205-255","article-title":"Examination of noninferiority, safety, and tolerability of lopinavir\/ritonavir and raltegravir compared with lopinavir\/ritonavir and tenofovir\/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results","volume":"12","author":"Reynes","year":"2011","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1500","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":"Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)","volume":"25","author":"Taiwo","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1505","series-title":"18th International AIDS Conference","author":"Mills","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib1510","series-title":"10th International Congess on Drug Therapy in HIV Infection","article-title":"Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naive HIV-infected patients: once-daily maraviroc plus lopinavir\/ritonavir","author":"Nozza","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib1515","doi-asserted-by":"crossref","first-page":"e5575","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib1520","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)\u2014associated tuberculous meningitis","volume":"52","author":"Torok","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1525","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1086\/652652","article-title":"Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa","volume":"50","author":"Makadzange","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1530","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e3282f4243b","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV","volume":"22","author":"Pulido","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1535","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","article-title":"A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy","volume":"198","author":"Cameron","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1540","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1310\/hct1006-368","article-title":"Monotherapy with lopinavir\/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)","volume":"10","author":"Nunes","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1545","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0b013e32833db9a1","article-title":"Randomized controlled study demonstrating failure of LPV\/r monotherapy in HIV: the role of compartment and CD4-nadir","volume":"24","author":"Gutmann","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1550","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/597119","article-title":"Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes","volume":"199","author":"Wilkin","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1555","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","article-title":"The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml","volume":"24","author":"Arribas","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1560","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3851\/IMP1519","article-title":"Treatment simplification to once daily darunavir\/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients","volume":"15","author":"Molto","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1565","series-title":"17th Conference on Retroviruses and Opportunistic Infections","article-title":"Efficacy and safety at 48 weeks of one-daily vs twice daily DRV\/r in treatment experienced HIV-1+ patients woth no DRV\/resistance associated mutations: the ODIN-trial","author":"Cahn","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib1570","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/jac\/dkq295","article-title":"Efficacy, safety and pharmacokinetics of 900\/100mg of darunavir\/ritonavir once daily in treatment-experienced patients","volume":"65","author":"Curran","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib1575","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jac\/dkr199","article-title":"96 week results from the MONET trial: a randomized comparison of darunavir\/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies\/ml at baseline","volume":"66","author":"Clumeck","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib1580","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136","volume":"24","author":"Katlama","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1585","series-title":"1er Congreso Nacional de Gesida","article-title":"Atazanavir\/ritonavir en monoterapia como mantenimiento en pacientes con supresi\u00f3n virol\u00f3gica: An\u00e1lisis primario a las 48 semanas del estudio OREY","author":"Pulido","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib1590","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV-1-infected patients receiving darunavir\/ritonavir monotherapy","volume":"204","author":"Lambert-Niclot","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1595","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkr504","article-title":"Long-term efficacy of darunavir\/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study","volume":"67","author":"Valantin","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib1600","series-title":"17th Conference on Retroviruses and Opportunistic Infections","article-title":"Fat tissue distribution changes in HIV-infected patients with viral suppression treated with DRV\/r monotherapy vs 2 NRTI+DRV\/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks","author":"Valentin","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib1605","doi-asserted-by":"crossref","first-page":"e22003","DOI":"10.1371\/journal.pone.0022003","article-title":"Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis","volume":"6","author":"Mathis","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib1610","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3851\/IMP1666","article-title":"Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen","volume":"15","author":"Ghosn","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1615","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1310\/hct1102-69","article-title":"Safety and efficacy of a 36-week induction regimen of abacavir\/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients","volume":"11","author":"Squires","year":"2010","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1620","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/QAD.0b013e32833bee1b","article-title":"Similar efficacy and tolerability of atazanavir compared with atazanavir\/ritonavir, each with abacavir\/lamivudine after initial suppression with abacavir\/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients","volume":"24","author":"Squires","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1625","series-title":"6th IAS Conference on HIV Pathogenesis, Treatment and Prevention","author":"Squires","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib1630","series-title":"8th Conference on Retroviruses and Opportunistic Infections","article-title":"Successful substitution of protease inhibitors with efavirenz in patients with undetectable viral loads: A prospective, randomized, multicenter, open-label study (DMP 049)","author":"Becker","year":"2001"},{"key":"10.1016\/j.eimc.2012.03.006_bib1635","series-title":"XIII International AIDS Conference","article-title":"Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA: results of a prospective, randomized, multicenter, open-label study (DMP 006-027)","author":"Katlama","year":"2000"},{"key":"10.1016\/j.eimc.2012.03.006_bib1640","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1086\/324629","article-title":"Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression","volume":"34","author":"Negredo","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1645","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/375598","article-title":"Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection","volume":"37","author":"Maggiolo","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1650","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1258\/ijsa.2009.008487","article-title":"Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients","volume":"21","author":"Campo","year":"2010","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1655","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00126334-200107010-00003","article-title":"Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study","volume":"27","author":"Ruiz","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1660","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1665","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1468-1293.2005.00320.x","article-title":"A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load","volume":"6","author":"Arranz Caso","year":"2005","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1670","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00002030-200005050-00006","article-title":"Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy","volume":"14","author":"Barreiro","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1675","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/605440","article-title":"Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)","volume":"49","author":"Negredo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1680","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00002030-200108170-00009","article-title":"Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA","volume":"15","author":"Clumeck","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1685","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/QAD.0b013e3280110cae","article-title":"Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells\/\u03bcL","volume":"20","author":"Manfredi","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1690","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Nevirapine-associated hepatotoxicity: no increased risk for females or high CD4 count in a single-centre HIV cohort","author":"Wolf","year":"2006"},{"key":"10.1016\/j.eimc.2012.03.006_bib1695","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1468-1293.2008.00552.x","article-title":"Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts","volume":"9","author":"De Lazzari","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1700","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/135965350701200305","article-title":"Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts","volume":"12","author":"Mocroft","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1705","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1310\/hct1101-11","article-title":"Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study","volume":"11","author":"Antela","year":"2010","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1710","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/528861","article-title":"Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study","volume":"46","author":"Wit","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1715","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1468-1293.2003.00139.x","article-title":"TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results","volume":"4","author":"Katlama","year":"2003","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1720","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/340312","article-title":"A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection","volume":"185","author":"Opravil","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1725","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/QAD.0b013e3282f3db2c","article-title":"Induction therapy with trizivir plus efavirenz or lopinavir\/ritonavir followed by trizivir alone in naive HIV-1-infected adults","volume":"22","author":"Mallolas","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1730","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(03)15018-0","article-title":"Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression","volume":"362","author":"Hoogewerf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1735","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1740","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e3280121ab1","article-title":"Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients","volume":"21","author":"Martinez","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1745","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","article-title":"Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine","volume":"19","author":"Fisac","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1750","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/QAD.0b013e328133f081","article-title":"Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification","volume":"21","author":"Martinez","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1755","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517497","article-title":"Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results","volume":"44","author":"Gatell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1760","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/QAI.0b013e31819a226f","article-title":"Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV\/r-containing HAART: the ATAZIP study","volume":"51","author":"Mallolas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1765","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1468-1293.2010.00827.x","article-title":"Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions","volume":"11","author":"Rubio","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1770","series-title":"17th International AIDS Conference","article-title":"Continuation of BID boosted PI vs switch to once-daily ATV\/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL study","author":"Moyle","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib1775","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAI.0b013e3181a5701c","article-title":"Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir","volume":"51","author":"Sension","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1780","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1086\/428091","article-title":"Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial","volume":"191","author":"Molina","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1785","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/135965350400900304","article-title":"Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach","volume":"9","author":"Negredo","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1790","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.aids.0000163933.14649.93","article-title":"Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine","volume":"19","author":"Barrios","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1795","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","article-title":"A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals","volume":"51","author":"Fisher","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1800","series-title":"17th International AIDS Conference","article-title":"Early improvement of limb fat content in patients switching from AZT\/3TC to FTC\/TDF (TVD): a 24 week interim analysis of the RECOMB Trial","author":"Mart\u00ednez","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib1805","series-title":"5th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"72 week outcomes following switch from AZT\/3TC to FTC\/TDF (TVD) vs continuing on AZT\/3TC. Final results of the RECOMB trial","author":"Ribera","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib1810","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jac\/dkp462","article-title":"Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate+emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients","volume":"65","author":"Valantin","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib1815","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e3181aa12d5","article-title":"A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir\/lamivudine or tenofovir\/emtricitabine in HIV-1-infected patients with virological suppression","volume":"51","author":"Martinez","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1820","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3851\/IMP1785","article-title":"Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir","volume":"16","author":"Saumoy","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1825","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32833562c5","article-title":"Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1830","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial","volume":"49","author":"Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1835","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0b013e32833f147f","article-title":"Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial","author":"Martin","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1840","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"51","author":"DeJesus","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1845","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/apc.2009.0259","article-title":"Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF","volume":"24","author":"Hodder","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1850","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/QAI.0b013e318198a0cc","article-title":"Safety of switching nevirapine twice daily to nevirapine once daily in virologically suppressed patients","volume":"50","author":"Podzamczer","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1855","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e3181ae35de","article-title":"Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study","volume":"51","author":"Towner","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1860","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Outcomes of patients switched from raltegravir within a virologocally suppressive regimen","author":"Harris","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib1865","series-title":"16th Conference on Retroviruses and Opportunistic Infections","article-title":"Switch from Enfuvirtide to Raltegravir in highly treatment-experienced patients: a randomized open label non-inferiority trial, Easier-ANRS 138","author":"De Castro","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib1870","series-title":"9th International Congess on Drug Therapy in HIV Infection","article-title":"Switch from enfuvirtide to raltegravir: a simplification option for heavily pretreated patients","author":"Gatti","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib1875","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/QAI.0b013e3181aa1398","article-title":"Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort","volume":"51","author":"Talbot","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1880","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1310\/hct1006-432","article-title":"Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression","volume":"10","author":"Santos","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1885","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/jac\/dkp366","article-title":"Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme","volume":"64","author":"Loutfy","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib1890","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1895","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1900","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1310\/hct1104-197","article-title":"Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial","volume":"11","author":"Vispo","year":"2010","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib1905","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0140-6736(10)60067-0","article-title":"Switching HIV therapies: competing host and viral factors","volume":"375","author":"Kilby","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib1910","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eimc.2008.02.007","article-title":"Resistencias genot\u00edpicas en pacientes con VIH-1 y grados de viremia persistentemente bajos","volume":"27","author":"Parra-Ruiz","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib1915","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/QAI.0b013e31819e721b","article-title":"Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay","volume":"51","author":"Lima","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib1920","series-title":"16th Conference on Retroviruses and Opportunistic Infections","article-title":"Virologic failure endpoint definition in clinical trials: Is using HIV-1 RNA threshold <200 copies\/ml better than <50 copies\/ml. An analysis of ACTG studies","author":"Ribaudo","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib1925","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/cid\/cir936","article-title":"Detection below 50 copies\/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy","volume":"54","author":"Doyle","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1930","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1935","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3851\/IMP1803","article-title":"Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients","volume":"16","author":"Gathe","year":"2011","journal-title":"Antivir Ther"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2012.03.006_bib1940","first-page":"A158","article-title":"Trends in HIV-1 non-B subtypes and drug resistance among Individuals with primary HIV infection in Spain since year 1997","volume":"16","author":"De Mendoza","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1945","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMra1004180","article-title":"Development of antiretroviral drug resistance","volume":"365","author":"Wainberg","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1950","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/QAD.0b013e3283316a5e","article-title":"Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials","volume":"23","author":"Katlama","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1955","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/650732","article-title":"Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure","volume":"50","author":"Llibre","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib1960","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-151-2-200907210-00003","article-title":"The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study","volume":"151","author":"Palella Jr.","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1965","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3851\/IMP1753","article-title":"Predicting antiretroviral drug resistance from the latest or the cumulative genotype","volume":"16","author":"Garcia","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1970","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1468-1293.2008.00607.x","article-title":"Genotypic antiretroviral drug resistance testing at low viral loads in the UK","volume":"9","author":"Cane","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib1975","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3851\/IMP1671","article-title":"Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir","volume":"15","author":"Llibre","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib1980","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0b013e3283427dcb","article-title":"Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy","volume":"25","author":"Goodman","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1985","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.aids.0000196174.80798.5b","article-title":"Once-daily directly observed therapy lopinavir\/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study","volume":"20","author":"Elzi","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib1990","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Second line lopinavir\/ritonavir monotherapy was inferior to tenofovir\/lamivudine\/lopinavir\/ritonavir in patients who failed NNRTI-regimen: HIV STAR study","author":"Bunupuradah","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib1995","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2000","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2005","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2010","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2020","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3851\/IMP1670","article-title":"Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score","volume":"15","author":"Schapiro","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib2035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0b013e32833677ac","article-title":"Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies","volume":"24","author":"Vingerhoets","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/QAI.0b013e3181bca669","article-title":"Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors","volume":"52","author":"Varghese","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2045","first-page":"62","article-title":"Update of the drug resistance mutations in HIV-1: Spring 2008","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2055","series-title":"6th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Exploratory analysis in the BENCHMRK studies at week 192: Late outcomes based on early virologic responses","author":"Eron","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib2060","series-title":"6th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Elvitegravir once daily is non-inferior to raltegravir twice daily in treatment- experienced patients: 48 week results from a phase 3 multicenter, randomized double-blind study","author":"Molina","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib2065","series-title":"5th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"S\/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor clinical isolates from patients experiencing virologic failure while on raltegravir therapy","author":"Underwood","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib2070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/QAI.0b013e3181b17f53","article-title":"Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection","volume":"52","author":"Imaz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.qai.0000147522.34369.12","article-title":"Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis","volume":"38","author":"Nieuwkerk","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00126334-200403010-00006","article-title":"The impact of adherence on CD4 cell count responses among HIV-infected patients","volume":"35","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/QAI.0b013e31819675e9","article-title":"The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time","volume":"50","author":"Lima","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00042560-200205010-00014","article-title":"Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients","volume":"30","author":"Garcia de Olalla","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2095","doi-asserted-by":"crossref","unstructured":"Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, Rourke SB, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV\/AIDS. Cochrane Database Syst Rev Issue 3. CD001442. DOI: 10.1002\/14651858.CD001442.pub2.","DOI":"10.1002\/14651858.CD001442.pub2"},{"key":"10.1016\/j.eimc.2012.03.006_bib2100","first-page":"e438","article-title":"Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators","volume":"3","author":"Mills","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib2105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1468-1293.2011.00928.x","article-title":"Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians","volume":"12","author":"Grierson","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/QAI.0b013e3181b065ee","article-title":"Profile of adherence to highly active antiretroviral therapy of patients older than 50 years old","volume":"52","author":"Pardi","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JGP.0b013e31819431bd","article-title":"Aging, neurocognition, and medication adherence in HIV infection","volume":"17","author":"Ettenhofer","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.eimc.2012.03.006_bib2120","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2125","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2130","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2135","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1086\/322698","article-title":"Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice","volume":"33","author":"Stone","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1089\/aid.2006.0120","article-title":"Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study","volume":"23","author":"Mu\u00f1oz-Moreno","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2012.03.006_bib2145","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1310\/NXJU-9ERQ-ADWW-UC5X","article-title":"Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice","volume":"5","author":"Duong","year":"2004","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib2155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/apc.2004.18.644","article-title":"Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System","volume":"18","author":"Deschamps","year":"2004","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2165","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/507526","article-title":"Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression","volume":"43","author":"Bangsberg","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/426595","article-title":"Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors","volume":"40","author":"Maggiolo","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1310\/hct0801-19","article-title":"Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study","volume":"8","author":"Cohen","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib2180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1468-1293.2009.00696.x","article-title":"Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up","volume":"10","author":"Knobel","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2185","doi-asserted-by":"crossref","first-page":"564","DOI":"10.7326\/0003-4819-146-8-200704170-00007","article-title":"Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes","volume":"146","author":"Nachega","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2190","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/jac\/dkq150","article-title":"Suboptimal adherence to darunavir\/ritonavir has minimal effect on efficacy compared with lopinavir\/ritonavir in treatment-na\u00efve. HIV-infected patients: 96 week ARTEMIS data","volume":"65","author":"Nelson","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2195","doi-asserted-by":"crossref","first-page":"e2783","DOI":"10.1371\/journal.pone.0002783","article-title":"Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels","volume":"3","author":"Parienti","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib2200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11904-007-0010-0","article-title":"Adherence-resistance relationships to combination HIV antiretroviral therapy","volume":"4","author":"Bangsberg","year":"2007","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"Suppl 3","key":"10.1016\/j.eimc.2012.03.006_bib2205","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1086\/533415","article-title":"Preventing HIV antiretroviral resistance through better monitoring of treatment adherence","volume":"197","author":"Bangsberg","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/QAD.0b013e3282f366ff","article-title":"Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance","volume":"22","author":"Gardner","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2215","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/QAD.0b013e328340a209","article-title":"A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people","volume":"24","author":"Bangsberg","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2220","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/QAD.0b013e3283499cd9","article-title":"Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy","volume":"25","author":"Llibre","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2225","first-page":"674","article-title":"Assessing treatment motivation among patients receiving antiretroviral therapy: A multidimensional approach","volume":"27","author":"Houston","year":"2012","journal-title":"Psychol Health"},{"key":"10.1016\/j.eimc.2012.03.006_bib2230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.qai.0000219771.97303.0a","article-title":"A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART","volume":"42","author":"Golin","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2235","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11904-009-0037-5","article-title":"Antiretroviral adherence interventions: translating research findings to the real world clinic","volume":"7","author":"Simoni","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.eimc.2012.03.006_bib2240","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e3181d9a330","article-title":"Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review","volume":"54","author":"Hart","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2245","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/cid\/cir537","article-title":"Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention","volume":"53","author":"Berg","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2250","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/00002030-200403050-00013","article-title":"Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study","volume":"18","author":"Kleeberger","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2255","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/339041","article-title":"Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature","volume":"34","author":"Falco","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2260","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1742-1241.2007.01385.x","article-title":"Long-term complications of antiretroviral therapy: lipoatrophy","volume":"61","author":"Waters","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eimc.2012.03.006_bib2265","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/QAD.0b013e32832d3b54","article-title":"Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy","volume":"23","author":"Kesselring","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2270","first-page":"317","article-title":"Hepatic safety profile of darunavir with low-dose ritonavir (DRV\/r) in HIV\/HCV coinfected and HIV monoinfected patients","volume":"34","author":"Morsica","year":"2011","journal-title":"New Microbiol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2275","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jac\/dkl074","article-title":"Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir","volume":"57","author":"Pineda","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2280","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1310\/hct0706-319","article-title":"Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir\/ritonavir","volume":"7","author":"Palacios","year":"2006","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib2285","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C","volume":"65","author":"Vispo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2290","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1097\/QAD.0b013e32833f9ce2","article-title":"Hepatic safety and tolerability in the maraviroc clinical development program","volume":"24","author":"Ayoub","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2295","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2300","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1086\/504323","article-title":"Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099","volume":"42","author":"Journot","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2305","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years","volume":"21","author":"Nelson","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2310","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients","volume":"8","author":"Cassetti","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib2315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/apc.2007.0052","article-title":"Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2320","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2325","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2330","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1468-1293.2010.00855.x","article-title":"Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure","volume":"12","author":"Tordato","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2335","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QAI.0b013e3181d05579","article-title":"Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men","volume":"55","author":"Wever","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2012.03.006_bib2340","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/QAI.0b013e31806007ed","article-title":"Metabolic issues associated with protease inhibitors","volume":"45","author":"Moyle","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2345","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-6405-5-5","article-title":"Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir\/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT","volume":"5","author":"Smith","year":"2008","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib2350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002030-200501280-00007","article-title":"Atazanavir plus ritonavir or saquinavir, and lopinavir\/ritonavir in patients experiencing multiple virological failures","volume":"19","author":"Johnson","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2355","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1468-1293.2008.00690.x","article-title":"Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers","volume":"10","author":"Tomaka","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2360","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.aids.0000233574.49220.de","article-title":"Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir","volume":"20","author":"Llibre","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2365","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1310\/hct0806-381","article-title":"The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy","volume":"8","author":"Madruga","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib2370","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","article-title":"Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study","volume":"19","author":"Brown","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2375","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc07-2013","article-title":"Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study","volume":"31","author":"De Wit","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eimc.2012.03.006_bib2380","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1086\/518619","article-title":"Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study","volume":"45","author":"Ledergerber","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2385","doi-asserted-by":"crossref","first-page":"E1666","DOI":"10.1152\/ajpendo.00550.2006","article-title":"Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults","volume":"292","author":"Fleischman","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.eimc.2012.03.006_bib2390","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","article-title":"HIV infection, inflammation, immunosenescence, and aging","volume":"62","author":"Deeks","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2395","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/QAI.0b013e31815e7251","article-title":"Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy","volume":"47","author":"Bozzette","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2400","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(02)11672-2","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV-1","volume":"360","author":"Holmberg","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2405","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","article-title":"clinical epidemiology group from the French hospital database, increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men","volume":"17","author":"Mary-Krause","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2410","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jac\/dkm414","article-title":"Predictive factors of vascular intima media thickness in HIV-positive subjects","volume":"61","author":"Bongiovanni","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2415","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/QAD.0b013e32811ebf79","article-title":"Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults","volume":"21","author":"Currier","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2420","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIRCULATIONAHA.107.189624","article-title":"Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy","volume":"118","author":"Currier","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.eimc.2012.03.006_bib2425","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2430","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1097\/QAD.0b013e3283493fb0","article-title":"Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study","volume":"25","author":"Rasmussen","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2435","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/655144","article-title":"Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study","volume":"51","author":"Lichtenstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2440","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/cir269","article-title":"Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era","volume":"53","author":"Bedimo","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2445","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2450","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/cir324","article-title":"Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s","volume":"53","author":"McComsey","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2455","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157016211794582687","article-title":"Fat tissue distribution changes in HIV-infected patients treated with lopinavir\/ritonavir. Results of the MONARK trial","volume":"9","author":"Kolta","year":"2011","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.eimc.2012.03.006_bib2460","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":"Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK","volume":"53","author":"Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2465","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","volume":"95","author":"Falutz","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eimc.2012.03.006_bib2470","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350501000606","article-title":"Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study","volume":"10","author":"Guaraldi","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib2475","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.300.5.509","article-title":"Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial","volume":"300","author":"Lo","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib2480","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2004.00190.x","article-title":"A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection","volume":"5","author":"Moyle","year":"2004","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2485","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1086\/656412","article-title":"Bone disease in HIV infection: a practical review and recommendations for HIV care providers","volume":"51","author":"McComsey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2490","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2495","first-page":"240","article-title":"Bone turnover markers in HIV disease","volume":"13","author":"Haskelberg","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2012.03.006_bib2500","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAI.0b013e31821ecf4c","article-title":"Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients","volume":"57","author":"Yong","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2505","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2510","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2515","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Effects of FTC\/TDF on bone mineral density in seronegative men from 4 continents: DEXA Results of the global iPrEx study","author":"Mulligan","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib2520","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"BMD Loss in HIV-men participating in a TDF PrEP clinical trial in San Francisco","author":"Liu","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib2525","article-title":"Documento de consenso sobre alteraciones osteoarticulares en la infecci\u00f3n por el","year":"2010","journal-title":"VIH"},{"key":"10.1016\/j.eimc.2012.03.006_bib2530","unstructured":"Tuset M, Mir\u00f3 JM, Codina C, Ribas J, editores. Gu\u00eda de interacciones farmacol\u00f3gicas en VIH [consultado 14 Dic 2011]. Disponible en: www.interaccionesvih.com"},{"key":"10.1016\/j.eimc.2012.03.006_bib2535","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1086\/652149","article-title":"Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy","volume":"50","author":"Evans-Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2540","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.antiviral.2009.07.017","article-title":"Pharmacokinetics and drug-drug interactions of antiretrovirals: an update","volume":"85","author":"Dickinson","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eimc.2012.03.006_bib2545","unstructured":"Back D, Gibbons S, Wilkins E, Burger D, Shapiro J, Marzolini C, et al. HIV Drug Interactions website [consultado 15 Dic 2011]. Disponible en: www.hiv-druginteractions.org"},{"key":"10.1016\/j.eimc.2012.03.006_bib2550","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkq448","article-title":"Emerging antiretroviral drug interactions","volume":"66","author":"Pham","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2555","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2010.02301.x","article-title":"Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition","volume":"268","author":"Josephson","year":"2010","journal-title":"J Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib2560","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17425255.2011.558839","article-title":"Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients","volume":"7","author":"Jimenez-Nacher","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2565","series-title":"17th Conference on Retroviruses and Opportunistic Infections","article-title":"Single-tablet, fixed-dose regimen of elvitegravir\/emtricitabine\/tenofovir disoproxil fumarate\/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster","author":"Cohen","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2570","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","article-title":"Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV","volume":"55","author":"German","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2575","series-title":"11th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Relative bioavailability and pharmacokinetics of Darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir","author":"Mathias","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2580","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","article-title":"Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity","volume":"87","author":"Mathias","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib2585","series-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir","author":"Ramanathan","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib2590","series-title":"7th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Role of intestinal absorption in increased tenofovir exposure when tenofovir disoproxil fumarate is co-administered with atazanavir or lopinavir\/ritonavir","author":"Ray","year":"2006"},{"key":"10.1016\/j.eimc.2012.03.006_bib2595","series-title":"7th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Mechanism of active tubular secretion of tenofovir and potential for a renal drug-drug interactions with HIV protease inhibitors","author":"Ray","year":"2006"},{"key":"10.1016\/j.eimc.2012.03.006_bib2600","series-title":"13th Conference on Retroviruses and Opportunistic Infections","article-title":"Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir","author":"Crane","year":"2006"},{"key":"10.1016\/j.eimc.2012.03.006_bib2605","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.ackd.2009.07.009","article-title":"Antiretroviral medications: adverse effects on the kidney","volume":"17","author":"Jao","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2610","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions","volume":"42","author":"Zimmermann","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2615","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir","volume":"43","author":"Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2620","series-title":"16th Conference on Retroviruses and Opportunistic Infections","article-title":"Tenofovir and PI use are associated with an increased prevalence of proximal renal tubular dysfunction in the Swiss HIV cohort study","author":"Fux","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib2625","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/157016210793499259","article-title":"Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight","volume":"8","author":"Chaisiri","year":"2010","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.eimc.2012.03.006_bib2630","series-title":"11th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Effect of efavirenz and darunavir\/ritonavir on bilirubun levels in healthy adult volunters: role of induction of UGT1A1 and bile efflux transporters","author":"Lee","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2635","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425255.2010.535811","article-title":"Pharmacokinetic evaluation of etravirine","volume":"6","author":"Dickinson","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2640","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/10895940-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of etravirine","volume":"48","author":"Sch\u00f6ller-Gy\u00fcre","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2645","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11534740-000000000-00000","article-title":"Pharmacokinetic interactions between etravirine and non-antiretroviral drugs","volume":"50","author":"Kakuda","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2650","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1128\/AAC.01600-07","article-title":"Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir","volume":"52","author":"Kharasch","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2655","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2660","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Effects of tipranavir\/ritonavir (TPV\/r) on the activity of cytochrome p450 (CYP) enzymes 1A2, 2C9, and 2D6 in healthy volunteers","author":"Vourvahis","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2665","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2165\/00003495-200767150-00010","article-title":"Maraviroc","volume":"67","author":"Carter","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.eimc.2012.03.006_bib2670","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2125.2008.03198.x","article-title":"Maraviroc: in vitro assessment of drug-drug interaction potential","volume":"66","author":"Hyland","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2675","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2146\/ajhp080206","article-title":"Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection","volume":"66","author":"Yost","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.eimc.2012.03.006_bib2680","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2165\/11203940-000000000-00000","article-title":"Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection","volume":"70","author":"Perry","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.eimc.2012.03.006_bib2685","unstructured":"Raltegravir. Merck Sharp & Dohme Ltd. Hertfordshire, Reino Unido. Septiembre 2010 [consultado 15 Dic 2011]. Disponible en: www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000860\/WC500037405.pdf"},{"key":"10.1016\/j.eimc.2012.03.006_bib2690","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/17425255.2010.513383","article-title":"Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies","volume":"6","author":"Burger","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2695","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003495-200868010-00009","article-title":"Raltegravir","volume":"68","author":"Croxtall","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.eimc.2012.03.006_bib2700","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2007.43.12.1146063","article-title":"Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1","volume":"43","author":"Evering","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.eimc.2012.03.006_bib2705","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1177\/0091270010387428","article-title":"Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor","volume":"51","author":"Brainard","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2710","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"An open, parallel group study to compare the pharmacokinetics, safety and toleration of a single oral dose of Maraviroc in subjects with mild and moderate hepatic impairment with subjects with normal hepatic function","author":"Abel","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2715","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis","author":"Agarwala","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2720","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/512086","article-title":"Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C","volume":"195","author":"Barreiro","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2725","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/00002030-200305020-00030","article-title":"High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400\/100mg twice a day) plus two nucleoside reverse transcriptase inhibitors","volume":"17","author":"Bossi","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2730","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Pharmacokinetics of Boosted PI and NNRTI in HCV\/HIV-co-infected Patients","author":"Breilh","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2735","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1128\/AAC.01115-06","article-title":"Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir","volume":"51","author":"Chen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2740","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0091270006292164","article-title":"Pharmacokinetics of nelfinavir in subjects with hepatic impairment","volume":"46","author":"Damle","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2745","series-title":"7th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Nevirapine plasma concentrations in HIV\/HCV and HIV infected patients, a case control study: NEVADOSE","author":"Dominguez","year":"2006"},{"key":"10.1016\/j.eimc.2012.03.006_bib2750","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"The impact of HCV\/HIV co-infection on nevirapine plasma concentration in a cohort of patients in Belgrade","author":"Dragovic","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2755","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Pharmacokinetics of atazanavir in HIV-1-HCV co-infected patients","author":"Gatti","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2760","series-title":"25th International Congress of Chemotherapy","article-title":"Potential role of TDM in dosing protease inhibitors in HIV-HCV co-infected patients with or without cirrhosis","author":"Gatti","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2765","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/00002030-200005260-00021","article-title":"Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis","volume":"14","author":"Gill","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2770","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/jac\/dkn383","article-title":"A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease","volume":"62","author":"Guaraldi","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2775","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/QAD.0b013e32830e011f","article-title":"The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir\/ritonavir in HIV-infected persons requiring hemodialysis","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2780","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Efficacy and safety of atazanavir in HIV-infected patients with liver cirrhosis","author":"Hermida Donate","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2785","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ndt\/gfg327","article-title":"Pharmacokinetics of tenofovir in haemodialysis","volume":"18","author":"Izzedine","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eimc.2012.03.006_bib2790","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00126334-199908150-00005","article-title":"Antiviral therapy for HIV patients with renal insufficiency","volume":"21","author":"Jayasekara","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib2795","first-page":"331","article-title":"Efavirenz-therapy in HIV-patients with underlying liver disease: importance of continuous TDM of EFV","volume":"12","author":"Katsounas","year":"2007","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.eimc.2012.03.006_bib2800","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00003088-200645110-00005","article-title":"Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment","volume":"45","author":"Kearney","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2805","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00003088-200645070-00003","article-title":"Tipranavir: a novel nonpeptidic protease inhibitor of HIV","volume":"45","author":"King","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2810","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Fosamprenavir\/ritonavir dose adjustment for patients with mild and moderate hepatic impairment (APV10017)","author":"Mallolas","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2815","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/FTD.0b013e318177209e","article-title":"Lopinavir\/ritonavir pharmacokinetics in HIV\/HCV-coinfected patients with or without cirrhosis","volume":"30","author":"Micheli","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.eimc.2012.03.006_bib2820","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200746010-00005","article-title":"Lopinavir\/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis","volume":"46","author":"Molto","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2825","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Nelfinavir pharmacokinetics in patients with HIV mono- and HIV-HCV co-infection","author":"Molto","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2830","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Higher plasma levels of Tipranavir in patients with more significant liver fibrosis and risk of liver toxicity","author":"Morello","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2835","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/ndt\/16.3.642","article-title":"Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency","volume":"16","author":"Paci-Bonaventure","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eimc.2012.03.006_bib2840","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0091270005284853","article-title":"Pharmacokinetics of lopinavir\/ritonavir in HIV\/hepatitis C virus-coinfected subjects with hepatic impairment","volume":"46","author":"Peng","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2845","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2125.2008.03238.x","article-title":"Efavirenz concentrations in HIV-infected patients with and without viral hepatitis","volume":"66","author":"Pereira","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2850","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jac\/dkn045","article-title":"Liver toxicity of antiretroviral combinations including atazanavir\/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis","volume":"61","author":"Pineda","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2855","series-title":"6th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Predictability of individual Nelfinavir concentrations at different time points for total systemic exposure in HIV and HIV\/HCV co-infected patients, with and without cirrhosis","author":"Regazzi","year":"2005"},{"key":"10.1016\/j.eimc.2012.03.006_bib2860","series-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pharmacokinetics of TMC125 in HIV-negative volunteers with mild and moderate hepatic impairment","author":"Sch\u00f6ller-Gy\u00fcre","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2865","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with impaired hepatic function","author":"Sekar","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2870","first-page":"279","article-title":"Liver function parameters in HIV\/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels","volume":"30","author":"Spagnuolo","year":"2007","journal-title":"New Microbiol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2875","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/clpt.1990.101","article-title":"Pharmacokinetics of zidovudine in patients with liver cirrhosis","volume":"47","author":"Taburet","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib2880","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Enfuvirtide does not require dose-adjustment in patients with chronic renal failure: the results of a pharmacokinetic study on enfuvirtide in HIV-1-infected patients with inpaired renal function (NP17586)","author":"Tebas","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib2885","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/AAC.44.4.821-826.2000","article-title":"Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function","volume":"44","author":"Veronese","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib2890","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1086\/426021","article-title":"Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction","volume":"40","author":"Wyles","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib2895","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/135965350701200815","article-title":"Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients","volume":"12","author":"Crespo","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib2900","series-title":"11th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Pharmacokinetics, safety, and tolerability of maraviroc in subjects with various degrees of renal impairment and normal renal function","author":"Vouvahis","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2905","series-title":"11th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Population modelling of maraviroc pharmacokinetic data when administered with and without saquinavir\/ritonavir in subjects with renal dysfunction","author":"McFadyen","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2910","series-title":"11th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Effect of hemodialysis in raltegravir clearance in HIV-infected patients with end stage renal disease","author":"Molto","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2915","series-title":"11th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Raltegravir and darunavir plasma pharmacokinetics in HIV-1 infected patients with advanced liver disease","author":"Tommasi","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2920","series-title":"11th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Hepatitis\/HIV co-infection without hepatic impairment does not alter lopinavir plasma concentrations in HIV-1 infeted adults","author":"Von Hentig","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2925","series-title":"18th International AIDS Conference","article-title":"Effect of moderate liver impairment on the multiple dose pharmacokinetics of ritonavir-boosted saquinavir in HIV patient","author":"Chang","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib2930","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/11530690-000000000-00000","article-title":"Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment","volume":"49","author":"Sekar","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2935","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1310\/hct1004-269","article-title":"Short-term effect of ritonavir-boosted atazanavir in hepatitis B and\/or C co-infected, treatment-experienced HIV patients","volume":"10","author":"Perez-Elias","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2012.03.006_bib2940","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/QAD.0b013e3283466f85","article-title":"The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score","volume":"25","author":"Rodriguez","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2945","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FTD.0b013e31821c2772","article-title":"Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens","volume":"33","author":"Regazzi","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.eimc.2012.03.006_bib2950","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00228-010-0904-4","article-title":"Assessing the impact of hepatitis C virus coinfection on lopinavir\/ritonavir trough concentrations in HIV-infected patients","volume":"67","author":"Calza","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib2955","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00002030-200410210-00008","article-title":"Survival in patients with HIV infection and viral hepatitis B or C: a cohort study","volume":"18","author":"Bonacini","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2960","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.23136","article-title":"Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus\/hepatitis C virus","volume":"50","author":"Macias","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2012.03.006_bib2965","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/135965350601100701","article-title":"Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C","volume":"11","author":"Macias","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib2970","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.aids.0000198087.47454.e1","article-title":"Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease","volume":"20","author":"Merchante","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2975","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2980","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.21757","article-title":"Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy","volume":"46","author":"Pineda","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2012.03.006_bib2985","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e3282f8b46f","article-title":"Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib2990","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib2995","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00126334-200312010-00004","article-title":"Grade 4 events are as important as AIDS events in the era of HAART","volume":"34","author":"Reisler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3000","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors","volume":"59","author":"Rivero","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"1 Suppl","key":"10.1016\/j.eimc.2012.03.006_bib3005","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"44","author":"Nunez","year":"2006","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.eimc.2012.03.006_bib3010","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1086\/381448","article-title":"Pitfalls of assessing hepatotoxicity in trials and observational cohorts","volume":"38","author":"Sabin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3015","series-title":"Table of grading severity of adult adverse experiences","year":"1996"},{"key":"10.1016\/j.eimc.2012.03.006_bib3020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib3025","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3030","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jac\/dkr083","article-title":"Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C","volume":"66","author":"Macias","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3035","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/jac\/dkr357","article-title":"Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV\/hepatitis C virus co-infected patients","volume":"66","author":"Neukam","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/apc.2011.0109","article-title":"Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400\/100mg once daily in HIV\/hepatitis C virus-coinfected patients","volume":"25","author":"Merchante","year":"2011","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3045","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients","volume":"196","author":"Labarga","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/jac\/dkn531","article-title":"Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C","volume":"63","author":"Meynard","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3055","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1128\/AAC.00632-09","article-title":"Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment","volume":"53","author":"Perez-Elias","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3060","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3065","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3070","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3080","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2012.03.006_bib3085","series-title":"49th Annual Meeting of the IDSA","article-title":"Boceprevir plus peginterferon\/ribavirin for the treatment of HCV\/HIV co-infected patients","author":"Sulkowski","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3090","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN-a2a and RBV in HIV\/HCV co-infected patients","author":"Sulkowski","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3095","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/592171","article-title":"Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe","volume":"198","author":"Soriano","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jhep.2008.04.010","article-title":"Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients","volume":"49","author":"Shores","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/01.aids.0000171412.61360.f8","article-title":"A cluster of acute hepatitis C virus infection among men who have sex with men \u2014results from contact tracing and public health implications","volume":"19","author":"Gotz","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3110","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.2174\/138161208784746851","article-title":"Therapy of acute hepatitis C: a review of literature","volume":"14","author":"Santantonio","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.eimc.2012.03.006_bib3115","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3120","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/135965350601100817","article-title":"Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals","volume":"11","author":"Vogel","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3125","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2893.2006.00749.x","article-title":"Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons","volume":"13","author":"Alvarez","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.eimc.2012.03.006_bib3135","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib3140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135965350400900108","article-title":"High rate of didanosine-related mitochondrial toxicity in HIV\/HCV-coinfected patients receiving ribavirin","volume":"9","author":"Moreno","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.qai.0000174649.51084.46","article-title":"Risk factors for symptomatic mitochondrial toxicity in HIV\/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy","volume":"40","author":"Bani-Sadr","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0b013e318040b2b6","article-title":"Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?","volume":"45","author":"Bani-Sadr","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3155","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","article-title":"Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir","volume":"13","author":"Vispo","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3160","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jac\/dkn420","article-title":"Efficacy of pegylated interferon plus ribavirin treatment in HIV\/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone","volume":"62","author":"Mira","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3851\/IMP1492","article-title":"The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients","volume":"15","author":"Amorosa","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3170","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/jac\/dkr362","article-title":"Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus","volume":"66","author":"Berenguer","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3175","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/135965350801300709","article-title":"Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin","volume":"13","author":"Laufer","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0b013e31817bbeb9","article-title":"Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV\/HCV-coinfected patients","volume":"49","author":"Quereda","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3185","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1097\/QAD.0b013e3283177f38","article-title":"Increase in serum bilirubin in HIV\/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin","volume":"22","author":"Rodriguez-Novoa","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3190","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers","author":"Van Heeswijk","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3195","series-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers","author":"Van Heeswijk","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3200","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Clinical pharmacology of boceprevir: Metabolism, excretion, and drug-drug interactions","author":"Kasserra","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3205","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection","volume":"40","author":"Van Bommel","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2012.03.006_bib3210","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","article-title":"Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus","volume":"189","author":"Dore","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3215","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1097\/00002030-200411190-00014","article-title":"Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment","volume":"18","author":"Schildgen","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","article-title":"A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B","volume":"166","author":"Lim","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3225","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/514750","article-title":"Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine","volume":"28","author":"Bessesen","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3230","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/QAI.0b013e3180314b46","article-title":"Hepatitis B virus genotypes and lamivudine resistance mutations in HIV\/hepatitis B virus-coinfected patients","volume":"44","author":"Ramos","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3235","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.aids.0000218550.85081.59","article-title":"Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy","volume":"20","author":"Matthews","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3240","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1097\/QAD.0b013e328349bbf3","article-title":"Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV\/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa","volume":"25","author":"Matthews","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3245","first-page":"40","article-title":"Treatment of HIV\/HBV coinfection: clinical and virologic issues","volume":"9","author":"Thio","year":"2007","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2012.03.006_bib3250","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1681\/ASN.2005040340","article-title":"Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease","volume":"16","author":"Schwartz","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3255","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/QAD.0b013e3280f774ee","article-title":"Chronic renal failure among HIV-1-infected patients","volume":"21","author":"Mocroft","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3260","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3282ef1bb4","article-title":"Chronic kidney disease in HIV infection: an urban epidemic","volume":"21","author":"Wyatt","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3265","series-title":"Tratamiento antirretroviral en situaciones especiales","first-page":"231","article-title":"Tratamiento antirretroviral en pacientes con insuficiencia renal","author":"Lozano","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3270","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1681\/ASN.2007040402","article-title":"Racial differences in end-stage renal disease rates in HIV infection versus diabetes","volume":"18","author":"Choi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3275","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1468-1293.2009.00693.x","article-title":"Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy","volume":"10","author":"Overton","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3280","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1468-1293.2008.00691.x","article-title":"Spectrum of chronic kidney disease in HIV-infected patients","volume":"10","author":"Campbell","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3285","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3290","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/QAD.0b013e328011ec40","article-title":"The nephrologist in the HAART era","volume":"21","author":"Izzedine","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3295","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/COH.0b013e3281ca6fbe","article-title":"Renal consequences of HIV and HIV therapy","volume":"2","author":"Bagnis","year":"2007","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3300","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1046\/j.1523-1755.2003.00031.x","article-title":"The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis","volume":"63","author":"Szczech","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.eimc.2012.03.006_bib3305","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/507538","article-title":"Antiretroviral medication errors among hospitalized patients with HIV infection","volume":"43","author":"Rastegar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3310","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3315","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Comparison of package-insert recommendations for renal dosing and prescribed dosing of products containing tenofovir: the VA experience","author":"Phillips","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib3320","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.eimc.2012.03.006_bib3325","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2012.03.006_bib3330","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/518667","article-title":"Tuberculosis and HIV coinfection: current state of knowledge and research priorities","volume":"196","author":"Friedland","year":"2007","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2012.03.006_bib3335","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0213-005X(11)70017-9","article-title":"Present-day treatment of tuberculosis and latent tuberculosis infection","volume":"29","author":"Perez-Camacho","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"RR-11","key":"10.1016\/j.eimc.2012.03.006_bib3340","first-page":"1","article-title":"Treatment of tuberculosis","volume":"52","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.eimc.2012.03.006_bib3345","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1157\/13123842","article-title":"Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad","volume":"26","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib3350","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0962-8479(94)90079-5","article-title":"Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group","volume":"75","author":"Gonzalez-Montaner","year":"1994","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3355","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","article-title":"Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis","volume":"28","author":"Ribera","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3360","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00002030-200303070-00024","article-title":"Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis","volume":"17","author":"Oliva","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3365","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis","volume":"41","author":"Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2012.03.006_bib3370","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350801300414","article-title":"Pharmacokinetics and 48-week efficacy of nevirapine: 400mg versus 600mg per day in HIV-tuberculosis coinfection receiving rifampicin","volume":"13","author":"Avihingsanon","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3375","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3380","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1086\/599115","article-title":"Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?","volume":"48","author":"Lalloo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3385","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/AAC.01468-08","article-title":"Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir","volume":"53","author":"Wenning","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3390","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/QAD.0b013e3283350f08","article-title":"Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis","volume":"24","author":"Burger","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3395","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1097\/QAD.0b013e3283136d95","article-title":"Optimal use of maraviroc in clinical practice","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3400","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e318189a7df","article-title":"Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir","volume":"50","author":"Haas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3405","unstructured":"Drug-induced hepatitis with saquinavir\/ritonavir + rifampin. AIDS Clin Care 2005; 17(3):32."},{"key":"10.1016\/j.eimc.2012.03.006_bib3410","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00002030-200106150-00018","article-title":"Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin","volume":"15","author":"Moreno","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3415","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/606056","article-title":"Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis","volume":"49","author":"Boulanger","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3420","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/598336","article-title":"Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy","volume":"48","author":"Jenny-Avital","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3425","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3430","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/0959-437X(95)80014-V","article-title":"Phylogeny and natural history of the primate lentiviruses, SIV and HIV","volume":"5","author":"Hirsch","year":"1995","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.eimc.2012.03.006_bib3435","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/00126334-200412150-00001","article-title":"Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups","volume":"37","author":"Tuaillon","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3440","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1371\/journal.ppat.0020010","article-title":"Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?","volume":"2","author":"Boyer","year":"2006","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.eimc.2012.03.006_bib3445","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/597802","article-title":"Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance","volume":"199","author":"Smith","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3450","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/135965350400900112","article-title":"Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV","volume":"9","author":"Parkin","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3455","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/AAC.01284-07","article-title":"In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors","volume":"52","author":"Desbois","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3460","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","article-title":"Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use","volume":"71","author":"Brower","year":"2008","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.eimc.2012.03.006_bib3465","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkl034","article-title":"Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy","volume":"57","author":"Rodes","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3470","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3475","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JVI.72.7.5425-5432.1998","article-title":"Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry","volume":"72","author":"Owen","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3480","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/088922204322996590","article-title":"Are fusion inhibitors active against all HIV variants?","volume":"20","author":"Poveda","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2012.03.006_bib3485","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/QAD.0b013e3283390db3","article-title":"Better mind the gap: addressing the shortage of HIV-positive women in clinical trials","volume":"24","author":"D\u2019Arminio","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3490","series-title":"18th International AIDS Conference","article-title":"Relevant changes in features at presentation among HIV infected women in the Spanish AIDS research network cohort (CoRis 1996-2008)","author":"Perez-Elias","year":"2010"},{"issue":"Suppl 5","key":"10.1016\/j.eimc.2012.03.006_bib3495","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/01.aids.0000298099.48990.99","article-title":"Gender, sexuality, and antiretroviral therapy: using social science to enhance outcomes and inform secondary prevention strategies","volume":"21","author":"Hirsch","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3500","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/jac\/dkm302","article-title":"Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review","volume":"60","author":"Nicastri","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3505","unstructured":"Millennium Challenge Corporation. Gender Integration Guidelines. 2011 [consultado 14 Dic 2011]. Disponible en: http:\/\/www.mcc.gov\/documents\/guidance\/guidance-2011001054001-genderintegration.pdf"},{"key":"10.1016\/j.eimc.2012.03.006_bib3510","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/09540121003758564","article-title":"Mirror, mirror on the wall: the face of HIV+ women in Europe today","volume":"22","author":"Nostlinger","year":"2010","journal-title":"AIDS Care"},{"key":"10.1016\/j.eimc.2012.03.006_bib3515","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/1471-2334-10-290","article-title":"Mapping HIV\/STI behavioural surveillance in Europe","volume":"10","author":"Dubois-Arber","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13691050802560336","article-title":"Challenges in researching life with HIV\/AIDS: an intersectional analysis of black African migrants in London","volume":"11","author":"Doyal","year":"2009","journal-title":"Cult Health Sex"},{"key":"10.1016\/j.eimc.2012.03.006_bib3525","series-title":"Centro de publicaciones del Ministerio de Sanidad y Consumo","article-title":"Plan Multisectorial frente a la infecci\u00f3n por VIH y el sida. Espa\u00f1a 2008-2012","year":"2007"},{"key":"10.1016\/j.eimc.2012.03.006_bib3530","article-title":"Documento de consenso de Gesida\/Plan Nacional sobre la Asistencia en el \u00e1mbito sanitario a las mujeres con infecci\u00f3n por","year":"2011","journal-title":"VIH"},{"key":"10.1016\/j.eimc.2012.03.006_bib3535","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/QAD.0b013e3280b0774a","article-title":"Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART","volume":"21","author":"Collazos","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3540","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/01.aids.0000161765.75663.27","article-title":"Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras","volume":"19","author":"Prins","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3545","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/QAI.0b013e3181609da8","article-title":"Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study)","volume":"47","author":"Tedaldi","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3550","series-title":"16th Conference on Retroviruses and Opportunistic Infections","article-title":"Meta-analysis of efficacy outcomes for treatment-na\u00efve and treatment-experienced HIV-infected women in randomized controlled clinical trials: 2000 to 2008","author":"Struble","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib3555","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-153-6-201009210-00002","article-title":"Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial","volume":"153","author":"Currier","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3560","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Association of race\/ethnicity and sex on outcomes in ACTG study A5202","author":"Smith","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3565","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jac\/dkq457","article-title":"Comparative gender analysis of the efficacy and safety of atazanavir\/ritonavir and lopinavir\/ritonavir at 96 weeks in the CASTLE study","volume":"66","author":"Squires","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3570","series-title":"1st International Workshop on HIV and Women","article-title":"Efficacy, safety and tolerability of lopinavir\/ritonavir in HIV-infected women: results of a meta-analysis of 7 prospective, randomized clinical trials through 48 weeks","author":"Hermes","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3575","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.maturitas.2009.09.001","article-title":"Women and HIV infection: the makings of a midlife crisis","volume":"64","author":"Santoro","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.eimc.2012.03.006_bib3580","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/09513590701253743","article-title":"Menopause symptoms in women infected with HIV: prevalence and associated factors","volume":"23","author":"Ferreira","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3585","series-title":"13th European AIDS Conference","article-title":"Antiretroviral therapy in women: trends over 12 years in the Swiss HIV cohort study","author":"Rosin","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3590","series-title":"13th European AIDS Conference","article-title":"Pooled week 96 efficacy and safety results from the double-blind, randomized, phase III trials comparing rilpivirine (RPV; TMC278) versus efavirenz (EFV) in treatment-na\u00efve, HIV-1 infected adults","author":"Stelbrink","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3595","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/sti.78.1.58","article-title":"Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication","volume":"78","author":"Sarner","year":"2002","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.eimc.2012.03.006_bib3600","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.aids.0000162344.73804.a1","article-title":"Do oestrogen receptors play a role in the pathogenesis of HIV-associated lipodystrophy?","volume":"19","author":"Barzon","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3605","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200501010-00004","article-title":"Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study","volume":"38","author":"Mulligan","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3610","first-page":"562","article-title":"Fat distribution in women with HIV infection","volume":"425","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3615","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1080\/09540121.2010.484454","article-title":"Self-efficacy and distress in women with AIDS: the SMART\/EST women's project","volume":"22","author":"Jones","year":"2010","journal-title":"AIDS Care"},{"key":"10.1016\/j.eimc.2012.03.006_bib3620","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00737-010-0158-2","article-title":"Correlates of HIV stigma in HIV-positive women","volume":"13","author":"Wagner","year":"2010","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.eimc.2012.03.006_bib3625","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/135965350901400106","article-title":"Body image is a major determinant of sexual dysfunction in stable HIV-infected women","volume":"14","author":"Luzi","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3630","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00002018-200629100-00004","article-title":"Neuropsychiatric complications of antiretroviral therapy","volume":"29","author":"Cespedes","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.eimc.2012.03.006_bib3635","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/QAI.0b013e31813e5e20","article-title":"Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender","volume":"46","author":"Smith","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3640","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002030-200402200-00014","article-title":"Reduced bone density in HIV-infected women","volume":"18","author":"Dolan","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3645","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e31804a7f4d","article-title":"Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women","volume":"45","author":"Dolan","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3650","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MED.0b013e3280109b6c","article-title":"Low bone-mineral density in patients with HIV: pathogenesis and clinical significance","volume":"13","author":"Yin","year":"2006","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"10.1016\/j.eimc.2012.03.006_bib3655","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/QAI.0b013e3181bf6471","article-title":"Short-term bone loss in HIV-infected premenopausal women","volume":"53","author":"Yin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3660","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/501015","article-title":"HIV infection and bone mineral density in middle-aged women","volume":"42","author":"Arnsten","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3665","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3851\/IMP1818","article-title":"Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study","volume":"16","author":"Barber","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3670","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/QAI.0b013e3181b628be","article-title":"Gender differences in discontinuation of antiretroviral treatment regimens","volume":"52","author":"Kempf","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3675","series-title":"18th International AIDS Conference","article-title":"Women antiretroviral use: durability, tolerance and virologic response when first attended for clinical care in the Spanish AIDS Research Network Cohort (CoRis, 1996-2008)","author":"Perez-Elias","year":"2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib3680","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1525-1497.2003.20122.x","article-title":"Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users","volume":"18","author":"Turner","year":"2003","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3685","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.idc.2008.05.006","article-title":"Gynecologic issues in the HIV-infected woman","volume":"22","author":"Cejtin","year":"2008","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2012.03.006_bib3690","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.aids.0000363778.58203.b6","article-title":"Safety of hormonal and intrauterine methods of contraception for women with HIV\/AIDS: a systematic review","volume":"23","author":"Curtis","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3695","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1783\/147118906775275055","article-title":"Contraception and HIV: what do we know and what needs to be done?","volume":"32","author":"Waters","year":"2006","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.eimc.2012.03.006_bib3700","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/humupd\/dmn049","article-title":"Contraception and HIV infection in women","volume":"15","author":"Heikinheimo","year":"2009","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.eimc.2012.03.006_bib3705","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0b013e3181eb5ff5","article-title":"Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188","volume":"55","author":"Vogler","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3710","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2125.2010.03885.x","article-title":"Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women","volume":"71","author":"Anderson","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3715","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/aje\/kwi116","article-title":"Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy","volume":"161","author":"Chu","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3720","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/13625180701829952","article-title":"Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives","volume":"13","author":"El-Ibiary","year":"2008","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.eimc.2012.03.006_bib3725","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00126334-200204150-00007","article-title":"Pharmacokinetic interaction between nevirapine and ethinyl estradiol\/norethindrone when administered concurrently to HIV-infected women","volume":"29","author":"Mildvan","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3730","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3735","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3851\/IMP1725","article-title":"The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women","volume":"16","author":"Sevinsky","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3740","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1724","article-title":"The effect of atazanavir\/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women","volume":"16","author":"Zhang","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib3745","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.10.002","article-title":"Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093","volume":"77","author":"Watts","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.eimc.2012.03.006_bib3750","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.fertnstert.2007.07.1348","article-title":"Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy","volume":"90","author":"Nanda","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.eimc.2012.03.006_bib3755","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/QAI.0b013e3181e49462","article-title":"Progestogen-only injectable hormonal contraceptive use should be considered in analysis of studies addressing the loss of bone mineral density in HIV-positive women","volume":"54","author":"Beksinska","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3760","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/QAD.0b013e32833a2537","article-title":"Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling","volume":"24","author":"Morrison","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3765","unstructured":"Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Sep. 14, 2011; pp 1-207 [consultado 1 Nov 2011]. Disponible en http:\/\/aidsinfo.nih.gov\/contentfiles\/PerinatalGL.pdf"},{"key":"10.1016\/j.eimc.2012.03.006_bib3770","first-page":"198","article-title":"Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy","volume":"13","author":"Senise","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2012.03.006_bib3775","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0b013e3283445811","article-title":"Relative time to pregnancy among HIV-infected and uninfected women in the Women's Interagency HIV Study, 2002-2009","volume":"25","author":"Linas","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3780","unstructured":"Polo R, Iribarren JA, De Jos\u00e9 MI, Mu\u00f1oz G\u00e1lligo E, coordinadores. Recomendaciones de la Secretar\u00eda del PNS, el GeSida, la SEGO y la AEP para el seguimiento de la infecci\u00f3n por el VIH con relaci\u00f3n a la reproducci\u00f3n, el embarazo y la prevenci\u00f3n de la transmisi\u00f3n vertical (diciembre 2007) [consultado 14 Dic 2011]. Disponible en: http:\/\/goo.gl\/A9Cwt"},{"key":"10.1016\/j.eimc.2012.03.006_bib3785","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1086\/318530","article-title":"Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies\/ml","volume":"183","author":"Ioannidis","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3790","article-title":"Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal","year":"2010","journal-title":"HIV transmission in the United States"},{"key":"10.1016\/j.eimc.2012.03.006_bib3795","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","article-title":"Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment, Pediatric AIDS Clinical Trials Group Protocol 076 Study Group","volume":"331","author":"Connor","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3800","series-title":"13th European AIDS Conference","article-title":"Atazanavir in pregnancy: a retrospective review of 155 cases to assess tolerability, toxicity, efficacy and the proportion of exposed neonates delivered preterm","author":"Samuel","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib3805","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1468-1293.2011.00927.x","article-title":"Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women","volume":"12","author":"Conradie","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3810","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1086\/503045","article-title":"Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?","volume":"193","author":"Cotter","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3815","unstructured":"Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 January 2010 [consultado 14 Dic 2011]. Disponible en: www.apregistry.com"},{"key":"10.1016\/j.eimc.2012.03.006_bib3820","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dkp447","article-title":"New therapeutic strategies for raltegravir","volume":"65","author":"Garrido","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2012.03.006_bib3825","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1097\/QAD.0b013e32833d8a50","article-title":"High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women","volume":"24","author":"McKeown","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3830","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1258\/ijsa.2011.010469","article-title":"Raltegravir in pregnancy: a case series presentation","volume":"22","author":"Taylor","year":"2011","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3835","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00126334-200407010-00002","article-title":"Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022","volume":"36","author":"Hitti","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3840","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00002030-200404090-00011","article-title":"Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery","volume":"18","author":"Fiore","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3845","unstructured":"Achievements in public health. Reduction in perinatal transmission of HIV infection--United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006; 55(21):592\u201397."},{"key":"10.1016\/j.eimc.2012.03.006_bib3850","unstructured":"Unaids. AIDS epidemic update 2010 [consultado 1 Nov 2011]. Disponible en: www.unaids.org\/globalreport\/default.htm 2010"},{"key":"10.1016\/j.eimc.2012.03.006_bib3855","doi-asserted-by":"crossref","first-page":"766","DOI":"10.7326\/0003-4819-154-11-201106070-00345","article-title":"Thirty years of HIV and AIDS: future challenges and opportunities","volume":"154","author":"Dieffenbach","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3860","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":"Viral load and heterosexual transmission of human immunodeficiency virus type 1, Rakai Project Study Group","volume":"342","author":"Quinn","year":"2000","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.eimc.2012.03.006_bib3865","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/01.aids.0000390705.73759.2c","article-title":"Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission","volume":"24","author":"Weber","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3870","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(11)60877-5","article-title":"HIV prevention transformed: the new prevention research agenda","volume":"378","author":"Padian","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib3875","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/QCO.0b013e3283422c8c","article-title":"\u2018Test-and-treat\u2019: the end of the HIV epidemic?","volume":"24","author":"Cambiano","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3880","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/QAD.0b013e32832b7dca","article-title":"Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis","volume":"23","author":"Attia","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3885","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/S0140-6736(10)60705-2","article-title":"Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis","volume":"375","author":"Donnell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib3890","series-title":"5th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARTV) different for men and women? Results from discordant couples in Rwanda and Zambia","author":"Sullivan","year":"2009"},{"key":"10.1016\/j.eimc.2012.03.006_bib3895","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAD.0b013e3283437c2b","article-title":"HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy","volume":"25","author":"Reynolds","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3900","doi-asserted-by":"crossref","first-page":"c2205","DOI":"10.1136\/bmj.c2205","article-title":"Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study","volume":"340","author":"Del Romero","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2012.03.006_bib3905","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/QAI.0b013e3181e9b6b7","article-title":"HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China","volume":"55","author":"Lu","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib3910","article-title":"Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples","author":"Anglemeyer","year":"2011","journal-title":"Cochrane Database of Systematic reviews"},{"key":"10.1016\/j.eimc.2012.03.006_bib3915","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0140-6736(08)61697-9","article-title":"Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model","volume":"373","author":"Granich","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib3920","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cid\/cir085","article-title":"The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco","volume":"52","author":"Charlebois","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3925","doi-asserted-by":"crossref","first-page":"e11068","DOI":"10.1371\/journal.pone.0011068","article-title":"Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco","volume":"5","author":"Das","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2012.03.006_bib3930","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study","volume":"376","author":"Montaner","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib3935","first-page":"315","article-title":"HIV-1 treatment as prevention: the good, the bad, and the challenges","volume":"6","author":"Smith","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib3940","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/cid\/ciq243","article-title":"The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection","volume":"52","author":"Gardner","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib3945","unstructured":"AIDS Vaccine Advocacy Coalition (AVAC). Global advocacy for HIV prevention. Ongoing PrEP trials [consultado 14 Dic 2011]. Disponible en: http:\/\/www.avac.org\/ht\/d\/sp\/i\/3507\/pid\/3507"},{"key":"10.1016\/j.eimc.2012.03.006_bib3950","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.eimc.2012.03.006_bib3955","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3960","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(11)60878-7","article-title":"Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women","volume":"378","author":"Karim","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2012.03.006_bib3965","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11904-010-0062-4","article-title":"Implementation science of pre-exposure prophylaxis: preparing for public use","volume":"7","author":"Underhill","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.eimc.2012.03.006_bib3970","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1056\/NEJMcp0904189","article-title":"Postexposure prophylaxis for HIV infection (clinical practice)","volume":"361","author":"Landovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib3975","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199711203372101","article-title":"A case-control study of HIV seroconversion in health care workers after percutaneous exposure, Centers for Disease Control and Prevention Needlestick Surveillance Group","volume":"337","author":"Cardo","year":"1997","journal-title":"N Engl J Med"},{"issue":"RR-9","key":"10.1016\/j.eimc.2012.03.006_bib3980","first-page":"1","article-title":"Updated U. S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis","volume":"54","author":"Panlilio","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.eimc.2012.03.006_bib3985","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/518349","article-title":"Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus","volume":"28","author":"Luque","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.eimc.2012.03.006_bib3990","series-title":"Recomendaciones del SPNS, Gesida, CEESCAT, SEIP y AEP sobre profilaxis postexposici\u00f3n frente al VIH, VHB y VHC en adultos y ni\u00f1os","author":"Polo","year":"2008"},{"key":"10.1016\/j.eimc.2012.03.006_bib3995","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002835.pub3","article-title":"Antiretroviral post-exposure prophylaxis for occupational HIV exposure","author":"Young","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eimc.2012.03.006_bib4000","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jech.2008.081463","article-title":"HIV prone occupational exposures: epidemiology and factors associated with initiation of post-exposure prophylaxis","volume":"63","author":"Zenner","year":"2009","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.eimc.2012.03.006_bib4005","series-title":"18th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Non-guideline post-exposure prophylaxis regimens for occupational percutaneous exposures to HIV+ source patients","author":"Hensic","year":"2011"},{"key":"10.1016\/j.eimc.2012.03.006_bib4010","year":"2010","journal-title":"HIV prophylaxis following occupational exposure"},{"key":"10.1016\/j.eimc.2012.03.006_bib4015","first-page":"174","article-title":"Occupational postexposure prophylaxis for HIV: The PEPline perspective","volume":"18","author":"Goldschmidt","year":"2010","journal-title":"Topics in HIV Medicine"},{"key":"10.1016\/j.eimc.2012.03.006_bib4020","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta13140","article-title":"Non-occupational postexposure prophylaxis for HIV: a systematic review","volume":"13","author":"Bryant","year":"2009","journal-title":"Health Technol Assess"},{"issue":"RR-2","key":"10.1016\/j.eimc.2012.03.006_bib4025","first-page":"1","article-title":"Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services","volume":"54","author":"Smith","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.eimc.2012.03.006_bib4030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1473-3099(09)70021-0","article-title":"Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies","volume":"9","author":"Boily","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib4035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/QAD.0b013e3283372d90","article-title":"Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART","volume":"24","author":"Jin","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib4040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/cid\/cir333","article-title":"A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV","volume":"53","author":"Roland","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib4045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1157\/13128270","article-title":"Demanda y prescripci\u00f3n de la profilaxis postexposici\u00f3n no ocupacional al VIH en Espa\u00f1a (2001-2005)","volume":"26","author":"Vives","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2012.03.006_bib4050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1468-1293.2010.00826.x","article-title":"Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis","volume":"11","author":"Tissot","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2012.03.006_bib4055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0b013e318230e885","article-title":"Australian gay men who have taken nonoccupational postexposure prophylaxis for hiv are in need of effective HIV prevention methods","volume":"58","author":"Zablotska","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2012.03.006_bib4060","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/sti.2010.046284","article-title":"Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City","volume":"87","author":"Mehta","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.eimc.2012.03.006_bib4065","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/QAD.0b013e328270385a","article-title":"Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis","volume":"21","author":"Dumond","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib4070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1258\/095646206775455829","article-title":"UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure","volume":"17","author":"Fisher","year":"2006","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib4075","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1097\/QAD.0b013e32833dfad1","article-title":"Tolerability of HIV postexposure prophylaxis with tenofovir\/emtricitabine and lopinavir\/ritonavir tablet formulation","volume":"24","author":"Tosini","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2012.03.006_bib4080","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0b013e3181e2f999","article-title":"Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance","author":"Sonder","year":"2010","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.eimc.2012.03.006_bib4085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3851\/IMP1955","article-title":"Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir\/ritonavir versus atazanavir each with zidovudine\/lamivudine","volume":"17","author":"Diaz-Brito","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2012.03.006_bib4090","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.eimc.2011.08.003","article-title":"An\u00e1lisis de costes y de coste\/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial","volume":"29","author":"Blasco","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X1200153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X1200153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T01:16:21Z","timestamp":1688260581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X1200153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":818,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0213005X1200153X"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2012.03.006","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}